Back to Studies
P1020A
A Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS-232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and Experienced HIV-infected Infants, Children and Adolescents
Study Status
Concluded
Locality
US & Non-US
DAIDS Number
10037
IND Number
60,878
Clinical Trials Link
Primary Protocol Team Members
Loading study documents...
Loading study sites...
Loading study protocol team...
Loading study press...
Loading study publications/presentations...